HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calif. Supreme Court Rules In Favor Of Glaxo, FDA On Prop 65 Warnings

This article was originally published in The Rose Sheet

Executive Summary

State regulations that conflict with FDA drug labeling are preempted by federal law, the California Supreme Court ruled April 15 in a case challenging the state's mandatory Prop 65 warning requirements for nicotine replacement therapy (NRT) products

You may also be interested in...



CTFA Weighs In As Prop 65 Amicus Brief Filed In Calif. Supreme Court

The Cosmetic, Toiletry and Fragrance Association amicus curiae brief in defense of nicotine-replacement therapy manufacturers involved in California Prop 65 litigation reflects the group's concern the labeling conflict involved could extend to other OTC drugs

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS012048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel